CCR9 and colitis: The decision to include patients with large bowel disease was based on experimental evidence that CCR9 and TECK are expressed in both small and large bowel[13]–[15], and emerging experimental evidence that CCR9 inhibition is effective in the MDR1a−/− mouse model of colitis [15].